The relatively recent success of targeting misfolded proteins has led to accelerated approvals, based on data including predictive surrogate biomarkers, of the anti-Aβ monoclonal antibody aducanumab (ADUHELM®) [13] for AD by the Food and Drug Administration (FDA) but not by the European Medicines Agency (EMA), and lecanemab (LEQEMBI®) [11] for AD as well as an anti-SOD1 drug, tofersen (QALSODYTM), for SOD1-ALS [19]. Here, SOD1 is linked to amyotrophic lateral sclerosis.